The natural history and the effects of gabapentin in amyotrophic lateral sclerosis

Journal of the Neurological Sciences

Volumn 160, Issue SUPPL. 1, 1998, Pages

  Mazzini, L ^a   Mora, G ^a   Balzarini, C ^a   Brigatti, M ^a   Pirali, I ^a   Comazzi, F ^a   Pastore, E ^a  

^a IRCCS   (Italy)

Author keywords

ALS; Gabapentin; Glutamate; Muscular strength; Survival

Indexed keywords

GABAPENTIN; GLUTAMIC ACID;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; HUMAN; NERVE DEGENERATION; PRIORITY JOURNAL;

ACETIC ACIDS; ADMINISTRATION, ORAL; ADULT; AGED; AMINES; AMYOTROPHIC LATERAL SCLEROSIS; CYCLOHEXANECARBOXYLIC ACIDS; DISABILITY EVALUATION; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 0031723703     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(98)00199-3     Document Type: Conference Paper

References (24)

1. Olney JW, Ho OL, Rhee V. Cytotoxic effects of acidic amino acids on the infant mouse central nervous system. Exp Brain Res 1971;14:61-76.
2. Meldrum B, Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci 1990;11:379-86.
3. Canu W, Billiard M, Baldy-Mouliner M. Fasting plasma and CSF amino acid levels in ALS. Acta Neurol Scand 1993;88:51-5.
4. Plaitakis A, Constantakakis E. Altered metabolism of excitatory amino acids, N-acetyl-aspartate and N-acetyl-aspartyl-glutamate in ALS. Brain Res Bull 1993;30:381-6.
5. Rothstein JD, Martin IJ, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in ALS. New Engl J Med 1992;326:1464-8.
6. Rothstein JD, Van Kammen M, Levey AI. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995;38:73-84.
7. Rothstein JD, Jin L, Dykes-Hoberg M, et al. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc Natl Acad Sci USA 1993;90:6591-5.
8. Bensimon G, Lacomblez L, Meininger V, and the ALS/Riluzole Study group. A controlled trial of riluzole in amyotrophic lateral sclerosis. New Engl J Med 1994;330;585-91.
9. Lacomblez L, Bensimon G, Leigh NP, Guillet P, Meininger V, for the ALS/Riluzole Study group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996;347:1425-31.
10. Taylor CP. Emerging perspectives on the mechanism of action of gabapentin. Neurology 1994;44(suppl 5):323-40.
11. Gurney ME, Cutting FB, Zhai P, et al. Benefit of vitamin E, riluzole and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996;39:147-57.
12. Miller RG, Moore D, Young LA, et al. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 1996;47:1383-8.
13. World Federation of Neurology Subcommittee on Motor Neuron Disease. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1994;124;(Suppl);96-107.
14. Mazzini L, Corrà T, Zaccala M, Mora G, Del Piano M, Galante M. Percutaneous endoscopie gastrostomy and enteral nutrition in amyotrophic lateral sclerosis. J Neurol 1995;242:695-8.
15. Norris FH, Calanchini PR, Fallat RJ, Panchari S, Jewett B. The administration of guanidine in amyotrophic lateral sclerosis. Neurology 1974;24:721-8.
16. Andres PL, Hedlund W, Finison LJ, Conlon T, Felmus M, Munsat TL. Quantitative motor assessment in amyotrophic lateral sclerosis. Neurology 1986;36:937-41.
17. Shoenberg JB, Beck GT, Bouhuys A. Growth and decay of pulmonary function in healthy blacks and whites. Respir Physiol 1978;33:1283-90.
18. Munsat TL, Andres PL, Finison L, Conlon T, Thibodeau L. The natural history of motoneuron loss in amyotrophic lateral sclerosis. Neurology 1988;38:409-13.
19. Brooks BR. Natural history of ALS: symptoms, strength, pulmonary function and disability. Neurology 1996;47(Suppl 2):S71-82.
20. Pradas J, Finison L, Andres PL, Thornell B, Hollander D, Munsat TL. The natural history of amyotrophic lateral sclerosis and the use of natural history controls in therapeutic trials. Neurology 1993;43:751-5.
21. Munsat TL. Issues in clinical trial design I: use of natural history controls. A protagonist view. Neurology 1996;47(Suppl 2):S96-7.
22. Rothman KJ. Placebo mania as medical knowledge accumulates, the number of placebo trials should fall. Br Med J 1996;313:3-4.
23. Loescher W, Hoenack D, Taylor CP. Gabapentin increases amono-axyacetic acid-induced GABA accumulation in regions of rat brain. Neurosci Lett 1991;28:150-4.
24. Rothstein JD, Kuncl RW Neuroprotective strategies in a model of chronic glutamate-mediated motor neuron toxicity. J Neurochem 1995;65:643-51.